X4 reports Q2 net income $90.8M on PRV sale; first XOLREMDI sales $0.6M

X4 Pharmaceuticals, Inc

2024-Q2 EPS reported $0.19 revenue$563,000

Q2 net income $90.8M vs net loss $55.7M YoY; includes $105M gain on sale of priority review voucher.
First product revenue $0.6M from XOLREMDI launch following FDA approval in April 2024 for WHIM syndrome.
Cash, equivalents, marketable securities $169.5M; operating runway into late 2025 (excl. future revenue).
Positive interim Phase 2 data for mavorixafor in chronic neutropenia; full results expected Nov 2024; Phase 3 4WARD trial started.
Plans to submit EMA approval for mavorixafor in WHIM syndrome by early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.